Stay Up
to Date
Stay Up
to Date
Breaking News,
Updates, & More
Breaking News,
Updates, & More
Click Here to
Subscribe
Click Here to
Subscribe

Oral Multiple Myeloma Medication Linked to Decreased Productivity Loss

TON - March 2018, Vol 11, No 1 - Conference Correspondent, ASH, Multiple Myeloma
Chase Doyle

 

Oral Multiple Myeloma Medication Linked to Decreased Productivity Loss

Atlanta, GA—A recent analysis of a commercial claims database suggests that oral therapy for multiple myeloma may help decrease the economic burden for patients and healthcare systems. According to data presented at ASH 2017, patients with multiple myeloma who received injectable therapy used significantly more disability benefits and incurred higher productivity costs than patients who received oral medications.

“The use of novel multiple myeloma drugs has been associated with improved therapeutic outcomes and survival, but the disease continues to pose a significant economic burden. Evaluating the economic implications and outcomes of available treatments is important to improve efficiency of care,” said David Merola, PharmD candidate, Bernard J. Dunn School of Pharmacy, Shenandoah University, Winchester, VA.

Productivity loss is common in patients with multiple myeloma, including lost days from work or inability to work because of symptoms or treatment, Mr Merola explained. Although the direct costs of illness have been well-­described in the literature, he noted, the indirect costs associated with multiple myeloma are understudied.

For this study, Mr Merola and colleagues analyzed the extent of workplace productivity loss in the United States among adults with multiple myeloma and its associated costs. These outcomes were compared among patients who received injectable versus oral multiple myeloma therapy. Mr Merola and colleagues used the Truven Health Analytics MarketScan Commercial Claims and Encounters with Medicare Supplemental Coordination of Benefits and Health and Productivity Management databases. Patients aged ≥18 years who were diagnosed with multiple myeloma between January 1, 2008, and December 31, 2014, were included in the study and were followed until December 31, 2015. The patients were analyzed 1 year before and 1 year after their first diagnosis.

Mr Merola and colleagues evaluated productivity loss using several key variables found in workplace absenteeism, short-term disability, and long-term disability claim files. The cost of productivity loss was calculated for each patient by multiplying the number of days lost to absenteeism by the average daily wage for all occupations in accordance with the US Bureau of Labor Statistics.

Fewer Workdays Missed

The study included 299 patients with newly diagnosed multiple myeloma; 73 patients received oral therapy and 226 received injectable agents. A regression analysis showed that treatment type was a significant predictor of productivity loss. Patients who received injectable therapy missed an average of 110 workdays in the 1 year postdiagnosis compared with 87 days (P <.001) for patients receiving only oral therapy. Treatment type was also a significant predictor of the cost of lost productivity. The lost productivity cost was $18,315 for patients who received injectable therapy and $14,429 for patients who only received oral drug therapy. The difference in valuated productivity losses between the study groups was also statistically significant at $3886 (P <.001).

According to Mr Merola and colleagues, an interrupted time-series analysis showed a significant increase in missed workdays per month after the initial diagnosis of multiple myeloma for both treatment groups. Patients who received injectable therapy experienced an immediate increase of 6.9 lost productivity days per month (P <.001) compared with 4.4 days per month in patients who received oral therapy alone (P <.001). The difference in these values was not statistically significant, said Mr Merola, although a strong trend was observed (2.5 days per month; P = .057).

Further studies are needed to elucidate the differences in outcome between patients receiving oral and injectable chemotherapies, Mr Merola and colleagues concluded.

Related Items
Overcoming Current Barriers to the Use of CAR T-Cell Therapy in the Community Setting
Chase Doyle
TON - August 2019, Vol 12, No 4 published on August 6, 2019 in Immunotherapy
Oncology Reimbursement Reform: Changes on the Horizon
Chase Doyle
TOP - August 2019, Vol 12, No 3 published on July 29, 2019 in ASCO
CAR T-Cell Therapy Targeting Solid Tumors
Chase Doyle
TOP - August 2019, Vol 12, No 3 published on July 29, 2019 in Immunotherapy
Economic Implications of Inpatient versus Outpatient Autologous Transplant for Patients with Multiple Myeloma
Chase Doyle
TON - April 2019, Vol 12, No 2 published on April 22, 2019 in Financial/Insurance Information
Oral Rigosertib plus Azacitidine Combination Shows Promising Results in High-Risk MDS
Chase Doyle
TON - April 2019, Vol 12, No 2 published on April 22, 2019 in Myelodysplastic Syndromes
Elotuzumab, Lenalidomide, and Dexamethasone Combination Demonstrates High Response Rate in High-Risk Smoldering Multiple Myeloma
Chase Doyle
TON - April 2019, Vol 12, No 2 published on April 22, 2019 in Multiple Myeloma
Inpatient Costs for Children and Young Adults with ALL Higher at Specialized Cancer Centers, but for a Good Reason?
Chase Doyle
TON - April 2019, Vol 12, No 2 published on April 22, 2019 in Financial/Insurance Information
Once-Weekly Carlzomib for Patients with Relapsed or Refractory Survival Multiple Myeloma Improves Progression-Free
Walter Alexander
TON - November 2018, Vol 11, No 5 published on November 28, 2018 in Multiple Myeloma
Timing of Palliative Care Consults Affects Healthcare Utilization in Elderly Patients with Pancreatic Cancer
Chase Doyle
TOP - November 2018, Vol 11, No 3 published on November 21, 2018 in HOPA
Discussing Costs with Your Patient Can Reduce Financial Toxicity
Chase Doyle
TON - September 2018, Vol 11, No 4 published on September 19, 2018 in Best Practices
Last modified: May 23, 2018